Department of Dermatology, Clinic of Orthopaedics, Rheumatology and Dermatology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Faculty of Medicine, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
PLoS One. 2024 Mar 8;19(3):e0299718. doi: 10.1371/journal.pone.0299718. eCollection 2024.
Topical photodynamic therapy (PDT) is an approved and widely used treatment for low-risk basal cell carcinoma (BCC), comprising two sessions with an interval of 1 week. Simplification of the treatment course can be cost-effective, easier to organize, and cause less discomfort for the patients.
We performed an investigator-initiated, single-blind, non-inferiority, randomized controlled multicentre study with the objective of investigating whether a simpler and more flexible PDT regimen was not >10% less effective than the standard double PDT in the treatment of primary, superficial, and nodular ≤2 mm-thick BCC and evaluate the cosmetic outcome. With a non-inferiority margin of 0.1 and an expected probability complete response of 0.85, 190 tumours were required in each group. Histologically verified BCCs from seven centres in Norway were randomly assigned (1:1) to either receive a new regimen of single PDT with one possible re-treatment of non-complete responding tumours, or the standard regimen. The primary endpoint was the number of tumours with complete response or treatment failure at 36 months of follow-up, assessed by investigators blinded to the treatment regimen. Intention-to-treat and per-protocol analyses were performed. The cosmetic outcome was recorded. The study was registered with ClinicalTrials.gov, NCT-01482104, and EudraCT, 2011-004797-28. A total of 402 BCCs in 246 patients were included; 209 tumours assigned to the new and 193 to the standard regimen. After 36 months, there were 61 treatment failures with the new and 34 failures with the standard regimen. Complete response rate was 69.5% in the new and 81.1% in the standard treatment group. The difference was 11.6% (upper 97.5% CI 20.3), i.e. > than the non-inferiority margin of 10%. Cosmetic outcomes were excellent or good in 92% and 89% following the new and standard regimens, respectively.
Single PDT with possible re-treatment of primary, superficial, and nodular ≤ 2-mm-thick BCC was significantly less effective than the approved standard double treatment. The cosmetic outcome was favorable and comparable between the two treatment groups.
局部光动力疗法(PDT)是一种已被批准并广泛应用于治疗低危基底细胞癌(BCC)的方法,包括两次治疗,间隔 1 周。简化治疗方案可以降低成本、更便于组织,并且减少患者的不适。
我们进行了一项由研究者发起的、单盲、非劣效性、随机对照多中心研究,旨在研究更简单、更灵活的 PDT 方案是否不比标准双 PDT 方案在治疗原发性、浅表性和结节状≤2 毫米厚的 BCC 时的疗效差>10%,并评估美容效果。在非劣效性边界为 0.1 和预期完全缓解概率为 0.85 的情况下,每组需要 190 个肿瘤。来自挪威七个中心的经组织学证实的 BCC 被随机分配(1:1)接受新的单次 PDT 方案治疗,或标准方案治疗。对于非完全缓解的肿瘤,可进行一次可能的重复治疗。主要终点是在 36 个月的随访中,通过对治疗方案不知情的研究者评估,肿瘤完全缓解或治疗失败的数量。进行了意向治疗和方案分析。记录了美容效果。该研究在 ClinicalTrials.gov 注册,NCT-01482104,和 EudraCT,2011-004797-28。共纳入 246 例患者的 402 个 BCC;其中 209 个肿瘤分配到新方案组,193 个肿瘤分配到标准方案组。36 个月后,新方案组有 61 例治疗失败,标准方案组有 34 例治疗失败。新方案组的完全缓解率为 69.5%,标准治疗组为 81.1%。差异为 11.6%(上 97.5%CI 为 20.3),即>10%的非劣效性边界。新方案组和标准方案组的美容效果分别为 92%和 89%,均为优秀或良好。
对于原发性、浅表性和结节状≤2 毫米厚的 BCC,单次 PDT 加原发性、浅表性和结节状≤2 毫米厚的 BCC 加可能的重复治疗,其疗效明显低于已批准的标准双治疗。两组治疗的美容效果均良好且相当。